Catheter ablation of atrial arrhythmias: state of the art

Geoffrey Lee, Prashanthan Sanders, Jonathan M Kalman

Catheter ablation is at the forefront of the management of a range of atrial arrhythmias. In this Series paper, we discuss the underlying mechanisms and the current role of catheter ablation for the three most common atrial arrhythmias encountered in clinical practice: focal atrial tachycardia, atrial flutter, and atrial fibrillation. The mechanisms of focal atrial tachycardia and atrial flutter are well understood, and these arrhythmias are amenable to curative catheter ablation with high success rates. In most cases, paroxysmal atrial fibrillation is initiated by triggers located within pulmonary vein musculature. Circumferential ablation to isolate this musculature is associated with high success rates for elimination of paroxysmal atrial fibrillation in selected populations. Because of the problem of recurrent pulmonary vein connection, more than one procedure will be needed in about 30% of patients, and new technologies are being developed to reduce this occurrence. The mechanisms that sustain persistent atrial fibrillation are not well understood and are the subject of continuing investigation. As such, ablation approaches and technologies for this arrhythmia are still evolving.

Introduction

Atrial arrhythmias include a range of different rhythm disturbances that encompass almost the full range of arrhythmia mechanisms. The three most frequently encountered arrhythmias, which are the focus of this review, are focal atrial tachycardia, atrial flutter, and atrial fibrillation. Generally, these arrhythmias respond poorly to antiarrhythmic drugs, and patients frequently have recurring and at times debilitating symptoms. Throughout the past decade, major technological advances in cardiac electrophysiology have brought catheter ablation to the forefront of treatment algorithms for these arrhythmias. In this Series paper, we provide an overview of the underlying mechanisms, relevant anatomy, and catheter-based treatment of these arrhythmias.

Classification of atrial arrhythmias

The nomenclature surrounding the classification of atrial arrhythmias continues to be unclear. Broadly, organised atrial tachycardias can be classified into two categories according to the arrhythmia mechanism: focal or macro-re-entry. Atrial fibrillation is a disorganised rhythm and its classification according to underlying mechanism is still evolving.

Focal atrial tachycardias are defined by early atrial activation from a discrete site with radial spread to the periphery. They can be paroxysmal or incessant and at times present as repetitive short bursts of tachycardia with one or more intervening sinus beats (figure 1). Such repetitive bursts can resemble short paroxysms of atrial fibrillation. On electrocardiogram (ECG), P waves might be discernible before each QRS complex. However, at rapid rates during sustained tachycardia, P waves can be difficult to distinguish because of superimposition on the preceding QRS or T wave. In this case, the arrhythmia appears as a regular supraventricular tachycardia.

Atrial flutter is due to a large re-entrant circuit (the macro-re-entry circuit; typically >2 cm in diameter) occurring around a central obstacle. This obstacle might be either an anatomic structure such as a pulmonary vein or valve annulus or a functional obstacle caused by heterogeneities in tissue electrical properties. The classic example of macro-re-entry is typical atrial flutter, but included within this category are various forms of atrial flutter. On ECG, atrial flutter is classically described as having a so-called saw-tooth appearance, attributable to the presence of continuous electrical activity.

Atrial fibrillation is defined by the presence of atrial fibrillatory waves that show variation in rate (interval) and morphology. The dominant classification of atrial fibrillation is according to arrhythmia duration and termination.1

ECG considerations

ECG cannot reliably distinguish tachycardia mechanism. No effective rate cutoff exists to differentiate focal atrial tachycardia from atrial flutter, and when viewing a 12-lead ECG snapshot, it can be difficult to distinguish between atrial fibrillation with coarse fibrillatory waves and atrial flutter. The distinction can be made with a careful analysis of P wave morphology and rate, which should be constant in atrial flutter and variable in atrial fibrillation.

Focal atrial tachycardia

General considerations

Focal atrial tachycardia is classified as a type of supraventricular tachycardia. It is the least common form of
this arrhythmia (after atrioventricular node re-entry and atrioventricular re-entry tachycardia) and accounts for just 10–15% of patients referred for catheter ablation of supraventricular tachycardia. Although generally benign, up to 25% of patients will present with frequent paroxysms or incessant activity, with a third of these patients eventually developing a tachycardia-mediated cardiomyopathy.4 The underlying mechanism(s) of focal atrial tachycardia might include abnormal automaticity, triggered activity, or re-entry.6 However, it is frequently not possible to precisely establish which of these mechanisms is responsible, and the distinction is of minor relevance to patients undergoing ablation.

Definitive data showing the superiority of one anti-arrhythmic drug over another in the treatment of focal atrial tachycardia are not available, and most information comes from small and mainly observational studies. Calcium-channel blockers and β blockers are often recommended as first-line agents because of their low side-effect profiles.7 In refractory cases, class Ic (flecainide and propafenone) or class III (sotalol and amiodarone) antiarrhythmics can be considered. The routine use of these drugs should be balanced against their uncertain and relatively poor efficacy and risk of significant side-effects including ventricular pro-arrhythmia.7 In view of the poor efficacy of drugs alone, catheter ablation of atrial tachycardia is considered a first-line7 therapy in patients with recurrent symptoms or those with incessant focal atrial tachycardias or a tachycardia-mediated cardiomyopathy.

Most focal atrial tachycardias occur in the absence of structural heart disease, although localised abnormalities at the tachycardia origin, including fibrosis, might be present.7 Tachycardia foci are not randomly distributed throughout the atria, but are localised to characteristic anatomical sites (figure 2). Roughly 75% occur in the right atrium, with the most common site of origin being the superior and middle parts of the crista terminalis.
Arrhythmias from this anatomic site have also been referred to as sinus node re-entry. In the left atrium, foci are most often noted at the ostium of the pulmonary veins.

Because of the characteristic anatomic clustering of atrial foci within the atria, the P-wave morphology on the surface ECG might provide important clues to the site of origin of the atrial tachycardia before catheter ablation.9 Kistler and colleagues9 developed an algorithm that prospectively localised the atrial site of origin in 93% of cases. Lead V1 was most useful in differentiating between left (positive P wave) and right (negative P wave) atrial focal sites.

Mapping and ablation of focal atrial tachycardia

Anatomic localisation of the atrial focus is undertaken during sustained tachycardia or in the presence of frequent atrial ectopy, which are necessary prerequisites for mapping. In some cases, the focus is quiescent and cannot be induced, precluding mapping. In the area of interest, precise mapping is done with a steerable ablation catheter to locate the earliest site of activation. The use of three-dimensional (3D) computerised mapping systems allows superimposition of colour-coded activation times on the atrial anatomy.10 This approach identifies a central region of earliest activity with radial propagation (figure 3). Radiofrequency energy is then delivered to this focus.

Catheter ablation of atrial tachycardia is a highly effective treatment with most studies reporting acute success rates in excess of 85–90%. Major complications are rare.4 The outcomes of patients presenting with cardiomyopathy secondary to incessant atrial tachycardia are excellent, with most patients recovering left ventricle function within months.5

Atrial flutter

General considerations

Atrial flutter represents a heterogeneous group of arrhythmias defined mechanistically by the presence of a large circuit around a central obstacle, which can be a fixed anatomical structure or a functional electrophysiological line of block. Generally, the unique anatomy of the atrium is an important determinant of the location of a flutter circuit. The most common form is best known as typical atrial flutter and is characterised by the presence of classic saw-tooth flutter waves in the inferior leads of the ECG.

The presence of atrial flutter usually suggests an underlying predisposition to atrial fibrillation, which will eventually be identified in most of these patients.11 Indeed, atrial flutter is generally initiated through a transitional phase of atrial fibrillation.12

The circuit for typical atrial flutter is located in the right atrium and is defined by well described anatomical barriers.13,14 In simple terms, the circuit can be viewed as a broad activation wavefront that rotates around the anteriorly located tricuspid annulus in the counterclockwise direction. Posteriorly, the crista terminals (which extends from the superior vena cava to the inferior vena cava on the posterior aspect of the atrium) acts as a conduction barrier that facilitates re-entry by preventing a short-circuiting of the annulus.15 At the crista terminals, cell-to-cell coupling is relatively poor in the transverse direction and therefore transverse conduction might be slow or blocked at this structure. The critical isthmus of the flutter circuit is in the floor of the right atrium between the inferior tricuspid annulus and the inferior vena cava—the cavotricuspid isthmus.16

Figure 4A shows the essential elements of typical atrial flutter. In about 15% of circuits, the wavefront rotates in a clockwise direction.

The circuits involved in atypical flutter are highly variable and involve a range of anatomical boundaries (figures 4, 5). Atypical flutters can be classified broadly into three categories: no previous atrial surgery; previous corrective atrial surgery (congenital and valvular heart disease); and previous atrial fibrillation ablation. Despite the range of different disorders and
operations, stereotypical anatomic locations have been described in each of these different settings.

In patients without previous atrial surgery, various circuits have been described. In the right atrium, these include circuits in the lateral wall of the atrium (free wall flutter) or around the inferior vena cava (lower loop re-entry with slow transverse conduction across the crista terminalis; figure 4B). In patients without previous atrial surgery, various circuits have been described. In the right atrium, these include circuits in the lateral wall of the atrium (free wall flutter) or around the inferior vena cava (lower loop re-entry with slow transverse conduction across the crista terminalis; figure 4B).
frequently occur around the mitral annulus or pulmonary veins.22 (figure 5).

In patients with previous atrial surgery, suture lines, scar, or prosthetic material can form the critical central barrier around which re-entry occurs, which has variously been referred to as incisional or scar-mediated re-entrant tachycardia. This disorder usually occurs in the context of surgical correction of congenital or valvular heart disease.21,24

Although the ECG pattern of typical flutter is characteristic, the flutter wave morphology of atypical flutters is highly variable and rarely gives a clue to precise anatomic location. Antiarrhythmic drugs are frequently ineffective and more than 50% of patients will eventually cross to a rate-control strategy because of an inability to maintain sinus rhythm.25 Catheter ablation is regarded as a first-line therapeutic option for patients with a first episode of typical atrial flutter26 and for flutter appearing after antiarrhythmic treatment of atrial fibrillation.27 Indications for ablation of atypical flutter include recurrent or poorly tolerated episodes and failed antiarrhythmic drug therapy.

Mapping and ablation of atrial flutter

Catheter mapping of atrial flutter involves activation, entrainment, and 3D computerised mapping. Activation mapping consists of catheters with several electrodes that can identify the direction of wavefront propagation. During entrainment mapping, pacing during tachycardia from different anatomic sites in the atrium identifies which sites are within the re-entrant circuit and which are activated passively.28 3D computerised mapping is used to reconstruct the 3D anatomy (with or without the use of an imported CT scan detailing atrial anatomy) with superimposition of colour-coded activation times to accurately show the location of even very complex circuits.29 Macro-re-entrant circuits will show as continuous loops, with activation timing spanning the cycle length and a region where early activation meets late activation (the so-called head meets tail of a re-entrant loop; figure 6).

Computerised mapping systems are generally not needed for ablation of simple circuits of known anatomic location, such as typical flutter. However, 3D mapping is of crucial importance for delineating the more complex circuits of atypical flutter, particularly in the context of abnormal atrial anatomy, multiple circuits, and regions of scar (figure 6). Successful ablation is dependent on identification of a narrow critical isthmus (figure 6) in the re-entrant circuit, which can be interrupted either with a line or focal point of ablation.

During ablation of typical atrial flutter, sequential or continuous radiofrequency lesions are given to form a contiguous linear lesion extending from the tricuspid annulus to the inferior vena cava, transecting the cavitricuspid isthmus (mean distance 2–3 cm).30 This ablation line prevents conduction at the narrowest point of the circuit and atrial flutter usually terminates just as the line is being completed. Mapping techniques are then used to confirm that the ablation line is complete (figure 7).31

The acute procedural success rate is now in excess of 95%, with a 5–10% incidence of flutter recurrence in 1–2 years of follow-up.32,33 Major complications are rare.34 A randomised study of ablation versus antiarrhythmic drugs as first-line treatment of typical flutter reported sinus rhythm in 80% and 36% of patients, respectively, at 21 month follow-up.35 The incidence of atrial fibrillation after ablation of atrial flutter is time-dependent, and with long-term follow-up it can occur in up to 80%.36 These data reinforce the need to consider continuing anticoagulation in patients who have a CHADS, score of greater than 1 (one point assigned for congestive heart failure [C], hypertension [H], age 75 years or older [A], or diabetes [D], and two for previous stroke or transient ischaemic attack [S]), despite undergoing successful flutter ablation, or to follow-up closely for development of atrial fibrillation.

Outcomes for ablation of atypical flutters are more variable and depend on the type of heart disease and extent of atrial pathology. Generally, patients who have had simpler surgical procedures (eg, atrial septal defect [ASD] repair, mitral valve repair) will have better outcomes than patients who have had several operations for complex congenital heart disease (eg, Mustard repair, Fontan repair). In these populations, ablation is generally used as
part of a general strategy that might also include open surgical approaches. Nevertheless, ablation strategies can yield highly effective palliation.

Atrial fibrillation
General considerations
Over the past decade, catheter ablation has evolved to become a routine procedure for selected patients with atrial fibrillation. This section will focus on the underlying mechanisms of atrial fibrillation in the context of catheter ablation, the common techniques, and the outcomes of these techniques.

Guidelines from the American College of Cardiology, American Heart Association, and European Society of Cardiology recommend catheter ablation for patients with atrial fibrillation who remain symptomatic despite optimum medical therapy (table). However, the 2012 expert consensus statement from the Heart Rhythm Society, European Heart Rhythm Association, and European Cardiac Arrhythmia Society on catheter and surgical ablation of atrial fibrillation includes ablation as a reasonable first-line option for selected patients with paroxysmal atrial fibrillation. These recommendations represent expert consensus and are not always supported by data from comparative trials. Additionally, the statement specifies that these complex and technically demanding procedures be done by operators with appropriate training in experienced centres.

In highly symptomatic patients with atrial fibrillation, catheter ablation has resulted in substantial improvement in quality of life. At present, no large prospective randomised studies have been undertaken that show an outcome benefit from atrial fibrillation ablation, either in terms of stroke reduction or mortality benefit, and information in this regard is largely restricted to single-centre retrospective series. As such, for asymptomatic patients or those who are minimally symptomatic, rate control is an acceptable alternative to rhythm control. The Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation trial (CABANA; NCT00911508) is a prospective multicentre randomised study (in progress) of ablation versus medical therapy in patients with atrial fibrillation and one or more risk factors for stroke. The primary endpoint is mortality and secondary endpoints include cardiovascular mortality and disabling stroke.

Mechanisms: focal drivers, rotors, and multiple wavefronts
In the past decade, understanding of the cellular and molecular mechanisms underlying atrial fibrillation has advanced significantly. Studies have emphasised the importance of ion channel remodelling, changes in signalling pathways, oxidative stress, altered calcium handling, changes in atrial architecture, and altered connexin expression in the pathogenesis of atrial fibrillation.

Until relatively recently, the multiple wavelet hypothesis was the dominant conceptual model of atrial fibrillation. The hypothesis is based on a computer model developed by Moe and colleagues and is supported by mapping data from animals and human beings. Atrial fibrillation was thought to be characterised by several randomly wandering wavefronts that vary in position, number, and size.

In recent years, increasing evidence suggests that focal drivers and rotors (one or more atrial re-entrant circuits)
have an important role in the underlying mechanism of atrial fibrillation.

The mechanisms underlying paroxysmal atrial fibrillation (defined by the presence of episodes that terminate spontaneously within 7 days) and persistent atrial fibrillation (episodes lasting longer than 7 days and not self-terminating) are considerably different.

In 1998, Haissaguerre and colleagues described the presence of focal drivers originating from within atrial muscular extensions into the pulmonary veins. Very high frequency electrical activity (>300–400 bpm) from a focal source caused non-uniform conduction to the atrium, resulting in atrial fibrillation. Since that seminal finding, others have also shown that pulmonary vein foci represent the crucial initiating trigger to paroxysmal atrial fibrillation in 85–95% of patients. In the remainder of patients, foci outside the pulmonary veins seem to be responsible. The pathophysiological processes leading to development of these focal triggers are not known. Furthermore, whether the underlying mechanism of this focal activity is due to enhanced automaticity, triggered activity, or localised pulmonary vein re-entry is unclear. Nevertheless, an appreciation of the importance of pulmonary vein musculature in initiation of paroxysmal atrial fibrillation has led to development of highly effective ablation strategies to electrically isolate these veins.

In patients with persistent atrial fibrillation, the mechanisms are less clear. Pulmonary vein foci might be important for arrhythmia initiation in a subset of patients. However, in those with more persistent atrial fibrillation and those with structural heart disease, mechanisms that maintain rather than initiate the arrhythmia play the dominant part. These mechanisms are located within atrial myocardium, and the development of atrial remodelling is of crucial importance to the persistence of atrial fibrillation. Atrial remodelling refers to the electrical and structural changes that develop in the atrium as a result of atrial fibrillation itself and the presence of a range of coexisting disorders. Heart failure, hypertension, valvular heart disease, and obstructive sleep apnoea lead to atrial structural changes or remodelling, including atrial enlargement and regional fibrosis, forming the prerequisite substrate for persistent atrial fibrillation.

The exact mechanism responsible for the maintenance of persistent atrial fibrillation is not known. Recently, accumulating evidence from animal studies has shown the important role of atrial rotors in driving persistent atrial fibrillation. Mapping studies of human beings have shown the presence of atrial rotors in patients with persistent atrial fibrillation. A recent study has shown that catheter ablation of these rotors might lead to termination of persistent atrial fibrillation. The efficacy of this potentially exciting new approach to the ablation of persistent atrial fibrillation will need to be verified by large multicentre studies.

Other mapping data from patients with persistent atrial fibrillation suggest that dissociation between the epicardial and endocardial atrial layers results in breakthrough wavefronts that continually renew and drive the atrial fibrillation process—a mechanism akin to multiple wavelet re-entry. These two mechanisms are not mutually exclusive. Importantly, in patients with different forms of structural heart disease, the underlying mechanism of atrial fibrillation is most probably quite heterogeneous.

The uncertainty surrounding the mechanism of persistent atrial fibrillation and our inability to establish precise mechanisms in individual patients is shown in the myriad of different ablative approaches to this arrhythmia and the disappointing success rates.

**Ablation of paroxysmal atrial fibrillation**

Pulmonary vein isolation is the cornerstone of catheter ablation for patients with paroxysmal atrial fibrillation. This method is an empirical approach based on the knowledge that most focal triggers occur within pulmonary vein muscular sleeves. Detailed assessment of the anatomic location of several triggers is not feasible. The current approach to isolation targets the proximal pulmonary vein antrum, thereby minimising the risk of stenosis (figure 8). The most widely used and assessed technique is that of point-by-point irrigated radiofrequency ablation. 3D mapping is routinely used to accurately delineate anatomy with or without the use of an imported CT scan (figure 8). More recently, in an attempt to simplify the procedure, various one-shot technologies for circumferential isolation of the pulmonary veins have been developed. The cryoballoon and a circumferential radiofrequency ablation catheter are the most advanced of these technologies. However, neither the promise of shorter procedure and fluoroscopy times nor the goal of improved efficacy and safety have been definitively realised. Irrespective of technology used, the endpoint for antral pulmonary vein ablation is demonstration of complete conduction block into and out of the pulmonary vein.

### Table: Class of consensus indications for catheter ablation of atrial fibrillation

<table>
<thead>
<tr>
<th>Indication class*</th>
<th>Class of consensus indications for catheter ablation of atrial fibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic atrial fibrillation refractory or intolerant to at least one class 1 or 3 antiarrhythmic drug</td>
<td></td>
</tr>
<tr>
<td>Paroxysmal: catheter ablation is recommended</td>
<td>I</td>
</tr>
<tr>
<td>Persistent: catheter ablation is reasonable</td>
<td>IIa</td>
</tr>
<tr>
<td>Longstanding persistent: catheter ablation could be considered</td>
<td>IIIb</td>
</tr>
<tr>
<td>Symptomatic atrial fibrillation before initiation of class 1 or 3 antiarrhythmic drug</td>
<td></td>
</tr>
<tr>
<td>Paroxysmal: catheter ablation is reasonable</td>
<td>IIa</td>
</tr>
<tr>
<td>Persistent: catheter ablation could be considered</td>
<td>IIIb</td>
</tr>
<tr>
<td>Longstanding persistent: catheter ablation could be considered</td>
<td>IIIb</td>
</tr>
</tbody>
</table>

*Class indicates level of evidence. Reproduced and modified from the 2012 Heart Rhythm Society, European Heart Rhythm Association, and European Cardiac Arrhythmia Society expert consensus statement on catheter and surgical ablation of atrial fibrillation, by permission of Springer.
Several randomised clinical trials have compared the outcomes of atrial fibrillation ablation with anti-arrhythmic drug therapy or with rate-control drugs alone.33 A meta-analysis of these trials described an overall success rate of catheter ablation of 77·8% compared with 23·3% for drug therapy.58 Several other meta-analyses of randomised clinical trials reported similar results.59

The most common reason for recurrence of paroxysmal atrial fibrillation after a pulmonary vein isolation procedure is pulmonary vein reconnection, which has been reported in 85–100% of patients undergoing a second procedure for symptomatic recurrence.60 Repeat procedures are needed in 20–30% of patients undergoing ablation of paroxysmal atrial fibrillation.

One meta-analysis specifically assessed success rates after single and repeat ablation procedures and took into account continuing need for antiarrhythmic treatment.61 The single and multiple procedure success rates of antiarrhythmic therapy were 57% and 71%, respectively, and the multiple procedure success rate of antiarrhythmic drugs was 77%.61 More recently, studies have reported long-term 5 year follow-up data62-64 in patients with paroxysmal atrial fibrillation, sinus rhythm was achieved in about 80–92% of patients after repeat procedures.62-64

Ablation of persistent atrial fibrillation
In paroxysmal atrial fibrillation, the ablation strategy is based on an understanding of the anatomic region crucial to arrhythmia mechanism (pulmonary vein muscle sleeves). In patients with persistent atrial fibrillation, especially those with longstanding (ie, >12 months) atrial fibrillation, the picture is much less clear. A wide range of approaches have been published targeting very varied putative arrhythmia mechanisms. Beyond circumferential pulmonary vein isolation, approaches to ablation of persistent atrial fibrillation continue to include linear ablation, ablation of complex fractionated atrial electrograms (CFAEs), ablation of autonomic ganglia, and
isolation of other venous structures including the coronary sinus and superior vena cava. Additionally, hybrid or stepwise approaches that include two or more of these procedures have been described. Each of these approaches is empirical: the mechanisms have not been shown in patients specifically and they are predicated on unproven assumptions about arrhythmia mechanism. This contrasts with ablation of atrial tachycardia and atrial flutter for which the individual patient-specific mechanism is clearly defined at the time of the procedure.

Disappointingly, the single procedure success rates have largely been under 50% and in some instances as low as 20–30%. A recent systematic review of outcomes of persistent atrial fibrillation ablation concluded that the varying ablation techniques (including pulmonary vein isolation alone, pulmonary vein isolation with linear ablation, pulmonary vein isolation with CFAE ablation, and the stepwise procedure) resulted in similar results (mean single procedure success rate of 47%).6 Clinical outcomes were improved with repeat procedures with success rates approaching 65%.

Studies with longer-term follow-up (2–5 years) have reported multiple procedure success rates ranging between 57% and 63%, and in many series persistent atrial fibrillation is an independent predictor of late recurrence.6,7 Other factors that have been associated with lower long-term success rates have included older age, increased left atrial size, obesity, sleep apnoea, and structural heart disease.6,7 However, findings have not been consistent and most trials have enrolled a relatively small number of patients with advanced age, marked left atrial enlargement, or advanced structural heart disease (including significant left ventricular dysfunction). Efficacy of catheter ablation in these subgroups needs further assessment.

Proarrhythmia: development of atrial tachycardia after atrial fibrillation ablation

New atrial tachycardias can appear for the first time after atrial fibrillation ablation. After simple pulmonary vein isolation, such arrhythmias are seen infrequently. However, with more extensive atrial ablation, especially that including linear ablation or widespread ablation of fractionated electrograms, recurrent atrial tachycardia can occur in 30–50% of patients. The most frequently reported mechanisms include atrial macro-re-entry (large circuits) or small re-entrant circuits (1–2 cm), both occurring around regions of previous ablation. These stable circuits, compared with atrial fibrillation, result in more rapid ventricular response rates, more frequently need cardioversion, and might actually be associated with an increase in symptoms.8,9 For these reasons, many laboratories now limit the amount of extensive ablation done.

Complications

The risk of major complications of radiofrequency catheter ablation of atrial fibrillation was previously reported to range from 3.9–4.5%.6,10 Recognised major complications include death (in 1 of 1000 patients), stroke, cardiac tamponade, atriopulmonary fistula, or clinically significant pulmonary vein stenosis. These studies incorporate results from a heterogeneous population undergoing a variety of ablation procedures between 1999 and 2007. With increasing experience, a high-volume centre reported that complication rates decreased from 11.1% in 2002, to 1.6% in 2010 (p<0.05), with no complications associated with permanent sequelae since 2005.11 In patients younger than 70 years with predominantly paroxysmal atrial fibrillation without significant structural heart disease, pulmonary vein antral isolation is safe and associated with a very low risk of major complications (<1%).12 Factors that have been associated with higher complication rates include older age, previous stroke, and advanced structural heart disease, but data are inconsistent.

Future challenges

For paroxysmal atrial fibrillation the major challenge is the creation of enduring pulmonary vein isolation, because pulmonary vein reconnection is the overwhelming reason for recurrence. Early data suggest that catheters that register tissue contact force and thereby improve lesion efficacy might result in lower rates of pulmonary vein reconnection.13,14 In patients with persistent atrial fibrillation, a better understanding of (probably heterogeneous) arrhythmia mechanisms is needed so that ablation approaches can be targeted to a clearly shown mechanism. Advances in technology have played a major part in our ability to ablate these arrhythmias; further improvements in catheter design and mapping capabilities will no doubt lead to better understanding and outcomes. By acting on the evolving substrate for atrial fibrillation, treatment of coexisting disorders might improve ablation outcomes or even slow clinical progression of atrial fibrillation so that ablation may be deferred. Studies are in progress.

Conclusion

Catheter ablation is now at the forefront of the treatment algorithm for a broad range of atrial arrhythmias. In patients with focal atrial tachycardia and typical atrial flutter, it is a first line therapy with efficacy in excess of 90%. For patients with a range of complex atypical flutters, it is a highly effective approach in those not readily controlled with antiarrhythmic drugs. For patients with previous atrial surgery or more complex congenital heart disease, late flutter recurrence or atrial fibrillation development is common, but ablation nevertheless might offer a highly effective palliation.

In symptomatic patients with atrial fibrillation, catheter ablation has resulted in substantial improvements in quality of life. Success rates in selected paroxysmal atrial fibrillation patients might be in excess of 80%, although several procedures are frequently needed, and complication rates have fallen to around 1% in low-risk populations.
More data are needed to understand the role and outcomes of ablation in broader subgroups, including elderly people and those with significant structural heart disease (including left ventricular dysfunction and atrial enlargement). For patients with persistent atrial fibrillation, the role of catheter ablation continues to evolve, as does our understanding of the crucial underlying mechanisms.

Contributors
GL did the detailed scientific literature search, drafted and revised the manuscript, and created the original figures. PS contributed to scientific literature inclusions; revised the manuscript, figures, and bibliography; and responded to the reviewers. JMK did the detailed literature search; revised the manuscript, figures, and bibliography; responded to the reviewers; and approved the final report.

Conflicts of interest
PS has served on the advisory board of Bard Electrophysiology, Biosense-Webster, Medtronic, St Jude Medical, Merck, and Sanofi-Aventis, and has received lecture fees or research funding from Bard Electrophysiology, Biosense-Webster, Medtronic, and St Jude Medical. JMK is the recipient of research funding and fellowship support from Medtronic, St Jude Medical, and Johnson & Johnson Medical. GL declares that he has no conflicts of interest.

Acknowledgments
GL is the recipient of a research scholarship from the National Health and Medical Research Council of Australia (NHMRC). JMK is the recipient of a grant from NHMRC (604908).

References


